L Liang1, R Shi1, X Liu1, X Yuan1, S Zheng1, G Zhang2, W Wang1, J Wang3, K England4, L E Via4, Y Cai4, L C Goldfeder4, L E Dodd5, C E Barry4, R Y Chen4. 1. Henan Provincial Chest Hospital, Zhengzhou, Henan. 2. Henan Public Health Clinical Center, Zhengzhou, Henan, China. 3. Clinical Monitoring Research Program, Clinical Research Directorate, Leidos Biomedical Research, Inc, Frederick, Maryland. 4. Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases. 5. Biostatistics Research Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Interferon-gamma (IFN-γ) release assays (IGRAs) are used to diagnose tuberculosis (TB) but not to measure treatment response. OBJECTIVE: To measure IFN-γ response to active anti-tuberculosis treatment. DESIGN: Patients from the Henan Provincial Chest Hospital, Henan, China, with TB symptoms and/or signs were enrolled into this prospective, observational cohort study and followed for 6 months of treatment, with blood and sputum samples collected at 0, 2, 4, 6, 8, 16 and 24 weeks. The QuantiFERON® TB-Gold assay was run on collected blood samples. Participants received a follow-up telephone call at 24 months to determine relapse status. RESULTS: Of the 152 TB patients enrolled, 135 were eligible for this analysis: 118 pulmonary (PTB) and 17 extra-pulmonary TB (EPTB) patients. IFN-γ levels declined significantly over time among all patients (P = 0.002), with this decline driven by PTB patients (P = 0.001), largely during the initial 8 weeks of treatment (P = 0.019). IFN-γ levels did not change among EPTB patients over time or against baseline culture or drug resistance status. CONCLUSION: After 6 months of effective anti-tuberculosis treatment, IFN-γ levels decreased significantly in PTB patients, largely over the initial 8 weeks of treatment. IFN-γ concentrations may offer some value for monitoring anti-tuberculosis treatment response among PTB patients.
BACKGROUND:Interferon-gamma (IFN-γ) release assays (IGRAs) are used to diagnose tuberculosis (TB) but not to measure treatment response. OBJECTIVE: To measure IFN-γ response to active anti-tuberculosis treatment. DESIGN:Patients from the Henan Provincial Chest Hospital, Henan, China, with TB symptoms and/or signs were enrolled into this prospective, observational cohort study and followed for 6 months of treatment, with blood and sputum samples collected at 0, 2, 4, 6, 8, 16 and 24 weeks. The QuantiFERON® TB-Gold assay was run on collected blood samples. Participants received a follow-up telephone call at 24 months to determine relapse status. RESULTS: Of the 152 TB patients enrolled, 135 were eligible for this analysis: 118 pulmonary (PTB) and 17 extra-pulmonary TB (EPTB) patients. IFN-γ levels declined significantly over time among all patients (P = 0.002), with this decline driven by PTBpatients (P = 0.001), largely during the initial 8 weeks of treatment (P = 0.019). IFN-γ levels did not change among EPTB patients over time or against baseline culture or drug resistance status. CONCLUSION: After 6 months of effective anti-tuberculosis treatment, IFN-γ levels decreased significantly in PTBpatients, largely over the initial 8 weeks of treatment. IFN-γ concentrations may offer some value for monitoring anti-tuberculosis treatment response among PTBpatients.
Authors: N Remus; J Reichenbach; C Picard; C Rietschel; P Wood; D Lammas; D S Kumararatne; J L Casanova Journal: Pediatr Res Date: 2001-07 Impact factor: 3.756
Authors: Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill Journal: PLoS One Date: 2010-09-01 Impact factor: 3.240
Authors: Grant Theron; Jonny Peter; Laura Lenders; Richard van Zyl-Smit; Richard Meldau; Ureshnie Govender; Keertan Dheda Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Samantha Ribeiro; Kelly Dooley; Judith Hackman; Carla Loredo; Anne Efron; Richard E Chaisson; Marcus B Conde; Neio Boechat; Susan E Dorman Journal: BMC Infect Dis Date: 2009-02-28 Impact factor: 3.090
Authors: Caian L Vinhaes; Deivide Oliveira-de-Souza; Paulo S Silveira-Mattos; Betania Nogueira; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Kiyoshi F Fukutani; Bruno B Andrade; Katrin D Mayer-Barber Journal: Cytokine Date: 2019-06-18 Impact factor: 3.861
Authors: Deivide Oliveira-de-Souza; Caian L Vinhaes; Maria B Arriaga; Nathella Pavan Kumar; Juan M Cubillos-Angulo; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Alan Sher; Subash Babu; Katrin D Mayer-Barber; Helder I Nakaya; Kiyoshi F Fukutani; Bruno B Andrade Journal: Sci Rep Date: 2019-05-29 Impact factor: 4.379